{"id":"placebo-for-ezetimibe","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1138","moleculeType":"Small molecule","molecularWeight":"409.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the efficacy of the active drug (Ezetimibe in this case) by comparison against a non-therapeutic baseline, allowing researchers to distinguish true drug effects from placebo response and natural disease progression.","oneSentence":"Placebo is an inert substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:06.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial for Ezetimibe (cholesterol-lowering agent)"}]},"trialDetails":[{"nctId":"NCT06450366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Hypercholesterolemia","enrollment":301},{"nctId":"NCT07442630","phase":"PHASE4","title":"Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides","status":"ACTIVE_NOT_RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2023-08-21","conditions":"Hypercholesterolemia","enrollment":88},{"nctId":"NCT07341958","phase":"NA","title":"INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-02-01","conditions":"Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)","enrollment":242},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT06742853","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-20","conditions":"Dyslipidemia","enrollment":81},{"nctId":"NCT05763875","phase":"PHASE3","title":"Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-15","conditions":"Hypercholesterolemia","enrollment":350},{"nctId":"NCT04669041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-08","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT05930028","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2023-07-13","conditions":"Essential Hypertension, Primary Hypercholesterolemia","enrollment":148},{"nctId":"NCT00650819","phase":"PHASE3","title":"Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06-01","conditions":"Hypercholesterolemia","enrollment":240},{"nctId":"NCT00552097","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-01","conditions":"Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II","enrollment":720},{"nctId":"NCT00653796","phase":"PHASE4","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":148},{"nctId":"NCT00653835","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Hypercholesterolaemia, Atherosclerosis","enrollment":153},{"nctId":"NCT00651274","phase":"PHASE4","title":"Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-01","conditions":"Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease","enrollment":144},{"nctId":"NCT00651391","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":28},{"nctId":"NCT00101439","phase":"PHASE3","title":"A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11-10","conditions":"Hypercholesterolemia","enrollment":58},{"nctId":"NCT00202878","phase":"PHASE3","title":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10-17","conditions":"Hypercholesterolemia, Myocardial Infarction","enrollment":18144},{"nctId":"NCT01611883","phase":"PHASE4","title":"A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-07-02","conditions":"Hypercholesterolemia","enrollment":152},{"nctId":"NCT00423579","phase":"PHASE4","title":"The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-07-01","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":120},{"nctId":"NCT00867165","phase":"PHASE3","title":"Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-05-21","conditions":"Primary Hypercholesterolemia","enrollment":138},{"nctId":"NCT02741245","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-06-09","conditions":"Hypercholesterolemia","enrollment":321},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT02550288","phase":"PHASE3","title":"A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2015-09-29","conditions":"Hypercholesterolemia","enrollment":309},{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT03768427","phase":"PHASE3","title":"Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-27","conditions":"Hypercholesterolemia","enrollment":454},{"nctId":"NCT00418834","phase":"PHASE3","title":"Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia","enrollment":1053},{"nctId":"NCT00276458","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":196},{"nctId":"NCT03867110","phase":"PHASE3","title":"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03-06","conditions":"Hypercholesterolemia","enrollment":628},{"nctId":"NCT03882905","phase":"PHASE3","title":"A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01-31","conditions":"Primary Hypercholesterolemia","enrollment":769},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT01420328","phase":"NA","title":"To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2011-05-01","conditions":"Inflammation","enrollment":20},{"nctId":"NCT00988364","phase":"PHASE4","title":"Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-03","conditions":"Metabolic Syndrome","enrollment":30},{"nctId":"NCT01308203","phase":"PHASE4","title":"Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease","status":"TERMINATED","sponsor":"Daniel A. Siniawski","startDate":"2011-10","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":32},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT04173793","phase":"PHASE2","title":"A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)","status":"COMPLETED","sponsor":"Akeso","startDate":"2019-11-18","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":109},{"nctId":"NCT04358432","phase":"PHASE2","title":"A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Akeso","startDate":"2020-05-13","conditions":"Hypercholesterolemia","enrollment":262},{"nctId":"NCT01375777","phase":"PHASE2","title":"Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-06","conditions":"Hyperlipidemia","enrollment":411},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01763827","phase":"PHASE3","title":"Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-21","conditions":"Hyperlipidemia","enrollment":615},{"nctId":"NCT01375764","phase":"PHASE2","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-28","conditions":"Hyperlipidemia","enrollment":160},{"nctId":"NCT01516879","phase":"PHASE3","title":"Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01-05","conditions":"Hypercholesterolemia","enrollment":905},{"nctId":"NCT02971033","phase":"PHASE2","title":"Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-04-16","conditions":"Chronic Hepatitis C","enrollment":2},{"nctId":"NCT03847506","phase":"PHASE4","title":"Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-07-05","conditions":"Hypertension, Hyperlipidemia","enrollment":127},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT05263778","phase":"PHASE4","title":"Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study","status":"UNKNOWN","sponsor":"Kaiser Permanente","startDate":"2022-03","conditions":"Cardiovascular Diseases, NSTEMI, STEMI","enrollment":500},{"nctId":"NCT00651404","phase":"PHASE3","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":137},{"nctId":"NCT00650689","phase":"PHASE3","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease","enrollment":122},{"nctId":"NCT00651144","phase":"PHASE1","title":"Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":40},{"nctId":"NCT00651014","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":82},{"nctId":"NCT00202904","phase":"PHASE4","title":"Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Hypercholesterolemia, Coronary Heart Disease","enrollment":81},{"nctId":"NCT00413972","phase":"PHASE3","title":"Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04","conditions":"Hypercholesterolemia","enrollment":392},{"nctId":"NCT00319449","phase":"PHASE4","title":"Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Hypercholesterolemia, Coronary Arteriosclerosis","enrollment":22},{"nctId":"NCT00423488","phase":"PHASE3","title":"Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07-12","conditions":"Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease","enrollment":93},{"nctId":"NCT00129402","phase":"PHASE3","title":"Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Hypercholesterolemia","enrollment":248},{"nctId":"NCT04844996","phase":"EARLY_PHASE1","title":"Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis","status":"COMPLETED","sponsor":"Mersin University","startDate":"2019-09-01","conditions":"Endometriosis","enrollment":18},{"nctId":"NCT00794677","phase":"PHASE4","title":"Effects of Ezetimibe on the Absorption of Oxidized Cholesterol","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2006-06","conditions":"Hypercholesterolemia","enrollment":26},{"nctId":"NCT04659525","phase":"PHASE4","title":"Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia","status":"UNKNOWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2020-11-01","conditions":"Hypercholesterolemia, CKD Stage 5, Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":50},{"nctId":"NCT02634580","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-27","conditions":"Hypercholesterolemia","enrollment":61},{"nctId":"NCT00477204","phase":"PHASE2","title":"Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":"Type 1 Diabetes Mellitus, Dyslipidemia","enrollment":9},{"nctId":"NCT01763905","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-24","conditions":"Hyperlipidemia","enrollment":307},{"nctId":"NCT01709513","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-09-30","conditions":"Hypercholesterolemia","enrollment":314},{"nctId":"NCT04397653","phase":"PHASE4","title":"Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients","status":"UNKNOWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2020-05-04","conditions":"Hypercholesterolemia, Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":50},{"nctId":"NCT03531905","phase":"PHASE2","title":"Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2018-05-09","conditions":"Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia","enrollment":242},{"nctId":"NCT03337308","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-10-23","conditions":"Hyperlipidemias","enrollment":382},{"nctId":"NCT01730053","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-11-30","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT00376246","phase":"PHASE4","title":"Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-09","conditions":"Endothelial Dysfunction","enrollment":28},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT02227784","phase":"PHASE3","title":"A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-10","conditions":"Hyperlipidemia","enrollment":366},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT00965055","phase":"PHASE3","title":"Ezetimibe in Patients Hypo-responsive to Statins","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2009-09","conditions":"High Cholesterol, Coronary Artery Disease","enrollment":2},{"nctId":"NCT01218204","phase":"PHASE2","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-14","conditions":"Dyslipidaemias, Dyslipidemias","enrollment":287},{"nctId":"NCT02055976","phase":"PHASE2","title":"Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":218},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT01984424","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-12-10","conditions":"Hyperlipidemia","enrollment":511},{"nctId":"NCT02260648","phase":"PHASE3","title":"A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2015-01","conditions":"Hypercholesterolemia","enrollment":149},{"nctId":"NCT02023879","phase":"PHASE3","title":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-16","conditions":"Hypercholesterolemia","enrollment":233},{"nctId":"NCT00559962","phase":"PHASE2","title":"Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Hyperlipidemia","enrollment":260},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT01723735","phase":"PHASE1","title":"Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-11","conditions":"Hypercholesterolemia","enrollment":79},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT01603758","phase":"PHASE1","title":"Physiological Study of Human Cholesterol Metabolism and Excretion","status":"COMPLETED","sponsor":"Richard E. Ostlund Jr., MD","startDate":"2014-01","conditions":"Coronary Heart Disease, Cardiovascular Disease, Dyslipidemia","enrollment":132},{"nctId":"NCT01849068","phase":"PHASE3","title":"Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study","status":"COMPLETED","sponsor":"Laval University","startDate":"2013-06","conditions":"Metabolic Syndrome X","enrollment":20},{"nctId":"NCT01644474","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":103},{"nctId":"NCT01266876","phase":"PHASE2","title":"Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":77},{"nctId":"NCT01730040","phase":"PHASE3","title":"Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-10","conditions":"Hypercholesterolemia","enrollment":355},{"nctId":"NCT02445352","phase":"PHASE3","title":"Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2014-07","conditions":"Primary Hypercholesterolemia","enrollment":379},{"nctId":"NCT02234544","phase":"PHASE4","title":"Effect of an Inhibitor of Cholesterol Absorption on Vitamin D Levels","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2014-10","conditions":"Vitamin D Deficiency","enrollment":52},{"nctId":"NCT00634140","phase":"NA","title":"The Influence of Ezetimibe on Gallbladder Function","status":"WITHDRAWN","sponsor":"Indiana University","startDate":"2009-08","conditions":"Chronic Acalculous Cholecystitis","enrollment":""},{"nctId":"NCT00738985","phase":"PHASE4","title":"Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors","status":"WITHDRAWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2009-11","conditions":"Cardiovascular Diseases, Hyperlipidemia","enrollment":""},{"nctId":"NCT02205775","phase":"PHASE3","title":"Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty","status":"TERMINATED","sponsor":"G. d'Annunzio University","startDate":"2010-05","conditions":"Stable Coronary Artery Disease Undergoing PCI","enrollment":280},{"nctId":"NCT02129231","phase":"PHASE2","title":"Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2012-02","conditions":"Oxidative Stress, Diabetic Polyneuropathy","enrollment":74},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT00268697","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-10","conditions":"Hypercholesterolemia","enrollment":1267},{"nctId":"NCT00701727","phase":"PHASE4","title":"Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study","status":"COMPLETED","sponsor":"Radiant Research","startDate":"2008-06","conditions":"Hypercholesterolemia","enrollment":31},{"nctId":"NCT01008345","phase":"PHASE4","title":"Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol","status":"COMPLETED","sponsor":"Hotel Dieu de France Hospital","startDate":"2008-09","conditions":"Coronary Artery Disease, Diabetes","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":515,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for Ezetimibe)","genericName":"Placebo (for Ezetimibe)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is an inert substance with no active pharmacological mechanism. Used for Control arm in Phase 3 trial for Ezetimibe (cholesterol-lowering agent).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}